Puma Biotech exclusively licenses neratinib from Pfizer
Client(s) Puma Biotechnology, Inc.
Jones Day advised Puma Biotechnology, Inc. with the IP diligence in connection with its exclusive license of rights to neratinib from Pfizer Inc. Puma is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. Neratinib is a phase III clinical candidate being tested as a treatment for HER2 positive breast cancer. Jones Day continues to advise Puma on patent portfolio strategy relating to neratinib.